Ultimovacs has entered into a collaboration with a leading Big Pharma company and a European oncology clinical trial group to evaluate the Company’s universal cancer vaccine, UV1, in an additional randomized, multi-center Phase II clinical trial. This third Phase II clinical trial will evaluate UV1 in a new cancer indication in combination with indication-specific standard of care cancer therapies different from those to be tested in the other Phase II clinical trials, INITIUM (malignant melanoma, 154 patients) and NIPU (mesothelioma, 118 patients). In the collaboration, Ultimovacs will supply UV1 and the Big Pharma company will supply its proprietary cancer treatment to the clinical trial group which will sponsor the trial. (27.05.2020)
Ultimovacs ASA Announces Collaboration with Big Pharma Company and Leading European Oncology Clinical Trial Group to Evaluate UV1 in a Third Phase II Clinical Trial
News
First Patient Dosed in both the INITIUM and NIPU Phase II Clinical Trials, Testing UV1 Against Metastatic Malignant Melanoma and Mesothelioma (15.06.20)
Technology
Ultimovacs is developing a universal cancer vaccine applicable across a broad spectrum of cancer types.
Clinical studies
Lead product tested in three clinical trials, strong results justifies the initiation of a registration trial.